Affinity Asset Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Affinity Asset Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,000	Closed	-$2.18M	–	97
2023 Q1	$2.18M	Sell	20,000 -25,000	-56%	-$2.76M	0.72%	41
2022 Q4	$5.12M	Buy	+45,000	New	+$3.74M	2.01%	18
2022 Q3	–	Sell	-75,000	Closed	-$5.98M	–	85
2022 Q2	$5.98M	Buy	75,000 +45,000	+150%	+$4.26M	2.52%	12
2022 Q1	$3.16M	Buy	+30,000	New	+$2.92M	0.5%	30
2021 Q4	–	Sell	-15,000	Closed	-$1.64M	–	86
2021 Q3	$1.64M	Sell	15,000 -10,000	-40%	-$1.04M	0.41%	47
2021 Q2	$2.34M	Sell	25,000 -10,000	-29%	-$920K	0.84%	29
2021 Q1	$3.22M	Sell	35,000 -10,000	-22%	-$844K	1.09%	23
2020 Q4	$3.29M	Buy	+45,000	New	+$3.34M	1.74%	16

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Affinity Asset Advisors's HZNP Position: Q2 2023 in Review

Affinity Asset Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 20,000 shares — an estimated $2.18M sold.

Affinity Asset Advisors first reported a position in HZNP in Q4 2020 and held it in 8 quarters. The position peaked at $5.98M in Q2 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Affinity Asset Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Affinity Asset Advisors sold 20,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $2.18M.
Affinity Asset Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 8 quarters.
Affinity Asset Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.98M in Q2 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.